Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

Similar articles for PubMed (Select 24135660)

1.

Platelet function and genetic testing.

Angiolillo DJ, Ferreiro JL, Price MJ, Kirtane AJ, Stone GW.

J Am Coll Cardiol. 2013 Oct 22;62(17 Suppl):S21-31. doi: 10.1016/j.jacc.2013.08.704. Review. No abstract available.

2.

[Antiplatelet therapy in coronary heart disease. Some problems and achivements].

Gratsianskiĭ NA.

Kardiologiia. 2010;50(6):4-21. Review. Russian.

PMID:
20659022
3.

Evolving role of platelet function testing in coronary artery interventions.

Sharma RK, Voelker DJ, Sharma R, Reddy HK, Dod H, Marsh JD.

Vasc Health Risk Manag. 2012;8:65-75. doi: 10.2147/VHRM.S28090. Epub 2012 Feb 8. Review.

4.

High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.

Marcucci R, Giusti B, Paniccia R, Gori AM, Saracini C, Valente S, Giglioli C, Parodi G, Antoniucci D, Gensini GF, Abbate R.

Platelets. 2012;23(8):586-93. doi: 10.3109/09537104.2012.658106. Epub 2012 Mar 5.

PMID:
22390861
5.

Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes.

Spiewak M, Małek ŁA, Kostrzewa G, Kisiel B, Serafin A, Filipiak KJ, Płoski R, Opolski G.

Kardiol Pol. 2009 Aug;67(8):827-34.

6.

Antiplatelets in acute coronary syndrome: personal perspectives.

Marcucci R, Cenci C, Cioni G, Lombardi A, Giusti B, Gensini GF.

Expert Rev Cardiovasc Ther. 2012 Dec;10(12):1487-96. doi: 10.1586/erc.12.153. Review.

PMID:
23253274
7.
8.

Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.

Coleman CI, Limone BL.

Am J Cardiol. 2013 Aug 1;112(3):355-62. doi: 10.1016/j.amjcard.2013.03.036. Epub 2013 Apr 27.

PMID:
23631863
9.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
10.

Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.

Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L.

J Am Coll Cardiol. 2010 Oct 26;56(18):1456-62. doi: 10.1016/j.jacc.2010.03.100.

11.

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.

Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL 3rd, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB; SWAP Investigators.

Thromb Haemost. 2013 Feb;109(2):347-55. doi: 10.1160/TH12-06-0378. Epub 2012 Dec 6.

PMID:
23223867
12.

Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.

Tantry US, Jeong YH, Navarese EP, Kubica J, Gurbel PA.

Expert Rev Cardiovasc Ther. 2013 Apr;11(4):447-62. doi: 10.1586/erc.13.20.

PMID:
23570358
13.

Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.

Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, Schork NJ, Teirstein PS, Topol EJ; GIFT Investigators.

J Am Coll Cardiol. 2012 May 29;59(22):1928-37. doi: 10.1016/j.jacc.2011.11.068.

14.

Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome.

Tello-Montoliu A, Jover E, Marín F, Bernal A, Lozano ML, Sánchez-Vega B, Pastor FJ, Hurtado JA, Valdés M, Vicente V, Rivera J.

Rev Esp Cardiol (Engl Ed). 2012 Mar;65(3):219-26. doi: 10.1016/j.recesp.2011.07.013. Epub 2011 Nov 23. English, Spanish.

PMID:
22116003
15.

Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.

Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro PJ, Saut N, Gaborit B, Pankert M, Cohen W, Lambert M, Beguin S, Morange PE, Bonnet JL, Alessi MC, Cuisset T.

Am J Cardiol. 2013 Apr 1;111(7):985-90. doi: 10.1016/j.amjcard.2012.12.013. Epub 2013 Jan 19.

PMID:
23340030
16.

Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.

Cuisset T, Hamilos M, Delrue M, Frère C, Verhamme K, Bartunek J, Saut N, Bonnet JL, Eijgelsheim M, Wijns W, Alessi MC, Barbato E.

Thromb Haemost. 2010 Apr;103(4):774-9. doi: 10.1160/TH09-06-0355. Epub 2010 Feb 2.

PMID:
20135061
17.

Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.

J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. doi: 10.1016/j.jacc.2012.03.050.

18.

Importance of platelets and platelet response in acute coronary syndromes.

Kottke-Marchant K.

Cleve Clin J Med. 2009 Apr;76 Suppl 1:S2-7. doi: 10.3949/ccjm.76.s1.01. Review.

20.

Unraveling myths of platelet function and genetic testing the road to making tailored antiplatelet therapy a reality.

Angiolillo DJ.

J Am Coll Cardiol. 2011 Jun 21;57(25):2484-6. doi: 10.1016/j.jacc.2011.01.040. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk